Heron Therapeutics amends Hercules Capital credit facility, cuts principal by $13.5 million

• Heron amended its credit facility with Hercules Capital, resetting financial covenants through 2027.
• Outstanding principal will be cut by up to USD 17.5 million, including USD 13.5 million at execution.
• A further USD 4 million reduction is scheduled on or before Sept. 15, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heron Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-341300), on August 10, 2026, and is solely responsible for the information contained therein.